Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Acceleron Pharma (XLRN) PT Raised to $62 at UBSJuly 10, 2018 8:01 AM Acceleron Pharma (XLRN) PT Raised to $74 at H.C. Wainwright Following Positive BELIEVE Results July 10, 2018 7:34 AM Celgene (CELG) Reports Phase III IMpassion130 Study Met Co-Primary Endpoint of Progression-Free SurvivalJuly 10, 2018 7:32 AM Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-ThalassemiaJuly 9, 2018 4:52 PM